Bexotegrast, an oral anti-fibrotic treatment candidate from Pliant Therapeutics, is being assessed in a Phase 2b clinical trial in people with idiopathic pulmonary fibrosis (IPF). Called BEACON-IPF, it intends to recruit about 270 patients at clinical sites around the globe. Details on site locations and when recruitment will start…
Bridge Biotherapeutics has joined the Prognostic Lung Fibrosis Consortium, known as PROLIFIC — a global nonprofit working to speed the development of personalized treatment strategies for pulmonary fibrosis (PF), The long-term goal of PROLIFIC is to develop tests to detect biomarkers of distinct stages of the rare…
patientMpower and Qureight have joined forces to accelerate the discovery of new prognostic markers for interstitial lung diseases (ILDs), a group of lung diseases characterized by scarring and inflammation that includes idiopathic pulmonary fibrosis (IPF). The collaboration will harness Qureight’s artificial intelligence (AI) capability along with patientMpower’s…
Dosing is complete in the Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis at risk of developing pulmonary hypertension. In the blinded part of the study, which is now complete, participants were randomly assigned to receive nitric oxide or a placebo administered…
One-year of high-dose AP01, Avalyn Pharma’s inhaled pirfenidone solution, slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF). That’s according to top-line data from the ongoing open-label extension AP01-005 study (2020-005103-39) that’s testing a 100 mg high dose of AP01, administered twice daily. The results align…
Individuals with idiopathic pulmonary fibrosis (IPF) who experience unintended weight loss are at significantly higher risks of being admitted to the hospital or dying within one year, a Danish study reported. Specifically, IPF patients with unintended weight loss were found to have a nearly 30 times higher risk of…
CS Pharmaceuticals (CSP) has entered into an exclusive in-licensing agreement with Daewoong Pharmaceutical to develop and commercialize bersiporocin, an oral experimental anti-fibrotic medication for idiopathic pulmonary fibrosis (IPF) and other respiratory diseases in the greater China region. “This will be the stepping stone towards becoming a game…
Strados Labs is teaming up with Boehringer Ingelheim to conduct a pilot study leveraging its RESP Biosensor, a first-of-its-kind device designed to remotely monitor key changes in lung sounds, cough, and other respiratory issues in people with idiopathic pulmonary fibrosis (IPF) and other lung disorders. In Boehringer…
Changes in blood levels of Krebs von den Lungen-6 — a protein produced by certain lung cells and known as KL-6 — can help predict the risk of disease progression in people with idiopathic pulmonary fibrosis (IPF) who’ve been treated with the anti-fibrotic medicines Esbriet (pirfenidone) and Ofev (nintedanib),…
PLN-74809, an oral treatment candidate for idiopathic pulmonary fibrosis (IPF), will now be called bexotegrast, its maker, Pliant Therapeutics, announced in a corporate update. The change came after the International Nonproprietary Names Expert Group selected bexotegrast as the unique generic, or nonproprietary, name for the experimental therapy. The company also announced…
Get regular updates to your inbox.
